ESC 2024: SELECT trial provides promising results for obesity-related HFpEF treatment Health August 30, 2024 The SELECT trial studied the use of semaglutide for patients with obesity-related diastolic heart failure (HFpEF). Image credit: Shutterstock/Komsan Loonprom…
